NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Hematopoietic Cell Transplantation, Version 2.2020

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP‐EBMT study

  2020cited by this paper
• Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003–2007 Versus 2013–2017 Cohorts

  2020cited by this paper
• Foundation for the Accreditation of Cellular Therapy

  2020cited by this paper
• Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency

  2019cited by this paper
• HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

  2019cited by this paper
• Ibrutinib for Chronic Graft-Versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.

  2019cited by this paper
• Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.

  2019cited by this paper
• A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor

  2019cited by this paper
• Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial

  2019cited by this paper
• Randomized Multicenter Trial of Sirolimus vs. Prednisone as Initial Therapy for Standard Risk Acute GVHD: BMT CTN 1501.

  2019cited by this paper
• Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

  2019cited by this paper
• Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract

  2019cited by this paper
• Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.

  2019cited by this paper
• Autologous Stem‐Cell Transplantation Outcomes for Relapsed Metastatic Germ‐Cell Tumors in the Modern Era

  2019cited by this paper
• Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.

  2019cited by this paper
• Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience

  2019cited by this paper
• Autologous Hematopoietic Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades

  2019cited by this paper
• FDA approves ruxolitinib for acute graft-versus-host disease

  2019cited by this paper
• Association between CMV and Invasive Fungal Infections After Autologous Stem Cell Transplant in Lymphoproliferative Malignancies: Opportunistic Partnership or Cause-Effect Relationship?

  2019cited by this paper
• Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.

  2018cited by this paper
• MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

  2018cited by this paper
• Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease.

  2018cited by this paper
• Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis

  2018cited by this paper
• Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single‐center study

  2018cited by this paper
• Anti‐thymocyte globulin improves survival free from relapse and graft‐versus‐host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia‐negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT

  2018cited by this paper
• EBMT—NIH—CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

  2018cited by this paper
• Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit

  2018cited by this paper
• Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease

  2018cited by this paper
• Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.

  2017cited by this paper
• Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.

  2017cited by this paper
• Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017cited by this paper
• Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

  2017cited by this paper
• Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.

  2017cited by this paper
• Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention

  2017cited by this paper
• High‐dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission

  2017cited by this paper
• Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

  2017cited by this paper
• High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

  2017cited by this paper
• Effect of Azithromycin on Airflow Decline–Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial

  2017cited by this paper
• Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation.

  2017cited by this paper
• Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

  2017cited by this paper
• The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease

  2017cited by this paper
• Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy.

  2017cited by this paper
• Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis

  2017cited by this paper
• A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation

  2016cited by this paper
• Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

  2016cited by this paper
• Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

  2016cited by this paper
• Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.

  2016cited by this paper
• Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

  2016cited by this paper
• Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

  2016cited by this paper
• Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

  2016cited by this paper
• Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

  2016cited by this paper
• Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.

  2016cited by this paper
• The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

  2016cited by this paper
• The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.

  2016cited by this paper
• A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation

  2016cited by this paper
• Tocilizumab for steroid refractory acute graft-versus-host disease

  2016cited by this paper
• International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

  2016cited by this paper
• Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation

  2016cited by this paper
• Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

  2015cited by this paper
• A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality.

  2015cited by this paper
• Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD

  2015cited by this paper
• Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.

  2015cited by this paper
• Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.

  2015cited by this paper
• Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease.

  2015cited by this paper
• Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

  2015cited by this paper
• Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.

  2015cited by this paper
• Response-guided therapy for steroid-refractory acute GVHD starting with very-low-dose antithymocyte globulin.

  2015cited by this paper
• The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials

  2015cited by this paper
• Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial

  2015cited by this paper
• Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease

  2015cited by this paper
• Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.

  2015cited by this paper
• How we treat chronic graft-versus-host disease.

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

  2015cited by this paper
• Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation.

  2015cited by this paper
• A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

  2015cited by this paper
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.

  2015cited by this paper
• NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

  2015cited by this paper
• Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.

  2015cited by this paper
• Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.

  2015cited by this paper
• Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

  2015cited by this paper
• A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

  2015cited by this paper
• Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation.

  2015cited by this paper
• Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.

  2014cited by this paper
• Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

  2014cited by this paper
• Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

  2014cited by this paper
• Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis

  2014cited by this paper
• Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

  2014cited by this paper
• Improvement of quality of life in patients with steroid‐refractory chronic graft‐versus‐host disease treated with the mTOR inhibitor everolimus

  2014cited by this paper
• Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors

  2014cited by this paper
• Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies.

  2014cited by this paper
• Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis

  2014cited by this paper
• Graft-Versus-Host Disease Prophylaxis after Transplantation: A Network Meta-Analysis

  2014cited by this paper
• Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning

  2014cited by this paper
• Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors

  2014cited by this paper
• A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

  2014cited by this paper
• Autologous transplantation and maintenance therapy in multiple myeloma.

  2014cited by this paper
• Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

  2014cited by this paper
• Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.

  2013cited by this paper
• Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

  2013cited by this paper
• Five things physicians and patients should question.

  2013cited by this paper

• Physical function and symptoms in adult hematopoietic stem cell transplantation patients, by severity of oral mucositis: a prospective study

  2025cites this paper
• Health care professionals’ understanding of contraindications for physical activity advice in the setting of stem cell transplantation

  2022cites this paper